



International Journal of PharmTech Research

CODEN (USA): IJPRIF, ISSN: 0974-4304, ISSN(Online): 2455-9563
Vol.9, No.12, pp 917-938, 2016

Resveratrol in combination with Ibuprofen against acute carrageenan-induced inflammation and hepatic insult: rectification of adenylate energy charge (AEC), anti-apoptotic, cell proliferation and DNA preservation potentials.

Rania F. Ahmed^{1*}, Omyma K. Radwan², Rofanda M. Bakeer³

¹Department of Pharmacology, Medical division, National Research Centre, (ID: 60014618), Dokki, 12622, Giza, Egypt.

²Department of Physiology, National Organization for Drug Control and Research, Giza, Egypt.

³Department of Pathology, Medical division, National Research Centre, (ID: 60014618), Dokki, 12622, Giza, Egypt.

Abstract: Inflammation is considered the quickest response to body organs damage and usually non-steroidal anti-inflammatory drugs (NSAIDs) are used in management of such condition, yet due to their undesirable side effects; other substitutes became of high demand. The present study aimed to investigate beneficial effects of combining resveratrol with ibuprofen in preventing carrageenan-induced inflammation and hepatic injury in rats. Results revealed that; combining resveratrol (40 mg/kg) with ibuprofen (40 mg/kg) lead to augmented anti-inflammatory and hepato-protective effects signified by partial prevention of carrageenan induced paw edema, reduced serum arachidonic acid, PGE₂, ALT and AST levels after both single and repeated administrations, decreased hepatic TNF- α level and 8-OHdG content, enhancement in hepatic tissue cell energy performance, declined oxidative and nitrosative stresses. Finally both histochemical H & E studies as well as caspase-3 and PCNA immunohistochemical examinations exposed the beneficial out comes from combining both treatments. As a conclusion; combining resveratrol with ibuprofen could be recommended over the use of ibuprofen alone in the treatment of inflammation.

Keywords: Carrageenan, Ibuprofen, Inflammation, Resveratrol.

Introduction

Inflammation is one of the first responses to cell and tissue damage and has been related with several physiological and pathological progressions by the initiation of immune responses within the damaged tissue. It results mainly by is the release of various inflammatory mediators for example; cytokines, prostaglandins, tumor necrosis factor alpha (TNF- α) bradykinin and histamine ¹.

Carrageenans are highly sulfated polysaccharides that are obtained from red seaweeds (Rhodophyceae). They have been widely used for decades as a thickener, stabilizer, or emulsifying agent in many processed foods and are also used in a variety of other products, such as cosmetics, toothpaste, room

deodorizers, and pharmaceuticals. Since the biological properties of carrageenan were surveyed by Di Rosa in 1972; potential hazards of oral, intraperitoneal and subcutaneous carrageenan administration, including intravascular coagulation, nephrotoxicity and liver histopathological changes have been investigated by several scientists. Single subcutaneous or intraperitoneal injection of carrageenan could induce serious liver injury and elevation in serum and tissue inflammatory markers levels that could persist for more than one week²⁻⁸.

Nonsteroidal anti-inflammatory drugs (NSAIDs) has long been considered as the first line treatments to reduce inflammation⁹. Ibuprofen is an over the counter (OTC) nonsteroidal anti-inflammatory drug (NSAID) that is commonly used as an analgesic, anti-inflammatory and anti-pyretic agent. It acts principally by inhibiting the activity of cyclooxygenase, which is the key enzyme for the synthesis of prostaglandins. The resultant inhibition of prostaglandin production leads to a reduction in inflammation, temperature and pain, both centrally and peripherally¹⁰⁻¹². Although usually tolerated by most patients, several case reports indicated the possibility of the occurrence of ibuprofen hepatotoxicity both at recommended dosages and at higher doses. Drug induced liver injury (DILI) in association with Ibuprofen was first reported in 1977. Subsequently it has been reported in various clinical situations where therapeutic doses of ibuprofen were associated with fatty liver, transaminitis and cholestatic hepatitis. There have been rare occasions where ibuprofen associated liver injury resulted in serious consequences requiring liver transplantation¹³⁻¹⁵. Consequently there is a prompt need to search for solutions to avoid those undesirable side effects where herbal supplements can be suitable candidates¹.

Resveratrol is a naturally occurring polyphenol that possesses several pharmacological activities including antioxidant, anti-inflammatory and hepatoprotective potentials. Resveratrol has been shown to prevent hepatic damage because of free radicals and inflammatory cytokines, induce anti-oxidant enzymes and elevate glutathione content. Resveratrol has also been shown to modulate varied signal transduction pathways implicated in liver diseases¹⁶⁻¹⁸.

Women take more medications than men and therefore have a higher chance of experiencing side-effects and drug-drug interactions. Regrettably; females are under-represented in basic research as well as in animal tests, and more importantly, in human clinical trials. For many years, the Food and Drug Administration (FDA) guidelines specifically precluded participation of females in many drug studies. Laboratory animals are predominantly male, even in studies of diseases that disproportionately affect more women. Males are preferred because they are thought to be less variable due to their constant hormone levels. This variability should not be ignored as hormones can play a role in many inflammatory responses. Clinically, women have been reported to have a 1.5–1.7 fold greater risk than men of experiencing an adverse drug reaction (ADR). Specifically, acute liver failure is a rare but very serious ADR that occurs more frequently in women. Women largely predominate among patients with NSAID-induced hepatitis. Establishing more adequate drug doses on women may serve as a prevention method in the future¹⁹⁻²³.

The present study aimed to investigate the augmentation of acute and sub-acute anti-inflammatory activity as a result of using combinations of resveratrol and ibuprofen; as well as the beneficial outcomes from such combinations in combating sub-acute carrageenan-induced hepatic insult in female rats.

2. Material and Methods

2.1. Animals

Adult female Wister rats, weighing 130-150 g each, purchased from the animal house at the National Research Centre (NRC, Giza, Egypt). All animals received human care in compliance with the guidelines of the EU Directive 2010/63/EU for animal experiments. Upon arrival, the animals were kept in a quiet place, housed eight per cage and acclimatized to a colony room with controlled ambient temperature (22 ± 1 °C), humidity ($50 \pm 10\%$) and a 12 hour natural light/dark cycle. They were fed a standard diet, water was provided *ad libitum* and they were acclimated for 7 days before entry into the subsequent study. They were allowed free access to water and food throughout the period of investigation. The experiments were performed with 8 rats per treatment group according to a randomized schedule.

2.2. Drugs and drug administration

Ibuprofen (Profen; sugar coated tablets, Kahira Pharmaceuticals and Chemical Industries Company; Under License From Abbott Laboratories Limited- USA and its subsidiary in Pakistan); the tablets were freshly suspended in distilled water prior to oral administration. Trans-resveratrol was provided as a generous gift from (Jing Tea LLC), it was provided as Harmoni-T micronized trans-resveratrol capsules for ingestion. The powder in the capsules was freshly dissolved in distilled water just before oral administration.

2.3. Experimental design.

Rats were divided into groups (8 rats each) and were treated as follows; Group (1): Carrageenan group. Group (2): Resveratrol low (20 mg/kg) **R20**. Group (3): Resveratrol high (40 mg/kg) **R40**. Group (4): Ibuprofen low (20 mg/kg) **I20**. Group (5): Ibuprofen high (40 mg/kg) **I40**. Group (6): Resveratrol low + Ibuprofen low (20 mg/kg + 20 mg/kg) **RI20**. Group (7): Resveratrol high + Ibuprofen high (40 mg/kg+ 40 mg/kg) **RI40**.

Treatments were orally administered on the first day concomitantly with carrageenan injection and then daily for the following three days at the same time as the first ingestions.

Blood samples were withdrawn under anaesthesia two times; the first time was on the first day after the last paw volume measurement (acute effect) and the second time on the fifth day 24h. after the last ingestions (sub-acute effect). In addition; blood samples were withdrawn from a group of eight normal animals to serve as **normal control** for the subsequent biochemical parameters. After that serum was separated and used for further biochemical analyses.

All groups; including the normal control group were then killed by decapitation, livers were isolated and kept at -80°C for further analyses.

N.B. (The normal group was kept in a separate cage in the same room and under the same conditions with food and water provided *ad libitum* throughout the whole time of the experiment. Both the normal and the carrageenan groups were given daily distilled water ingestions; 5ml/kg p.o)

2.4. Experimental procedure.

2.4.1. Carrageenan- induced rat paw edema:

Animals were deprived of food for 12 h prior to experiment and only water was given *ad libitum*. First group (carrageenan group) received distilled water (5ml/kg p.o). Other groups received the corresponding drug treatments in distilled water orally. Concomitantly; carrageenan suspension (0.1 ml of 1% w/v suspension in 0.9% saline solution) was injected into the sub planter region of right hind paw of animals. Immediately before carrageenan injection, the paw volume was measured (initial paw volume) using plethysmometer (Harvard Apparatus Co. Model No. LE7500, USA). Thereafter, the paw volume was measured after 1, 2 and 3 h after carrageenan administration. The difference between initial (V_b) and subsequent readings (V_t) gave the change in edema volume for the corresponding time. % Edema of control (E_c) and of treated (E_t) were used to calculate percentage (%) inhibition and (%) edema volume by using following formula:

$$\% \text{ Edema} = [(V_t - V_b) / V_b] \times 100, \% \text{ Inhibition} = [1 - (E_t / E_c)] \times 100.$$

V_t = edema volume after different time intervals, V_b = basal edema volume, (E_c) = % Edema of control (carrageenan), (E_t) = % Edema of treated ²⁴.

2.4.2 Biochemical Analysis.

2.4.2.1 Determination of serum ALT (u/ l) and AST (u/ l) levels:

Alanine aminotransaminase (ALT) and Aspartate aminotransaminase (AST) activities were determined spectrophotometrically using commercial biochemical kits according to manufacturer's instructions. All of the samples and standards were assayed in duplicate, as suggested by the manufacturer (Biodiagnostic Co., Egypt)²⁵.

2.4.2. 2. Determination of serum PGE2 (pg/ml)

The PGE2 levels were measured using an enzyme-linked immunosorbent assay (ELISA) according to manufacturer's instructions. All of the samples and standards were assayed in duplicate, as suggested by the manufacturer (Kono biotech Co.,LTD, China)²⁶.

2.4.2.3. Determination of serum arachidonic acid (pg/ml)

Arachidonic fatty acid was determined by using gas chromatography (GC) ²⁷. Arachidonic fatty acid were purchased in the triglyceride form and stored at -35°C until used. Fatty acid, solvents and other chemicals were obtained from Sigma-Aldrich. Standards for calibration were prepared in hexane: chloroform (1:1) and combined into a single fatty acid mixture. The extraction of serum samples were prepared with folch reagent, chloroform: methanol (2:1) then vortex for 2 min and centrifuged for 10 min. at 4000 rpm. Standard and samples were allowed to evaporate at room temperature prior to derivatization. Esterification get by mixing the supernatant with 2ml of (95 methanol : 5 sulphuric acid) then put in oven about 80°C for 2 hrs then extracted with 2 ml hexane finally samples were ready for injection in the GC set loop.

2.4.2.4. Determination of tissue GSH ($\mu\text{mol/g tissue}$) and GSSG ($\mu\text{mol/g tissue}$) levels by HPLC:

The thiols compounds of oxidized and reduced glutathione were detected by HPLC system of Agilent HP 1200 series (USA) that consisted of quaternary pump, a column oven, Rheodine injector and $20\mu\text{l}$ loop, UV variable wavelength detector. The report and chromatogram taken from Chemstation program purchased from Agilent. $30\text{ cm} \times 3.9\text{ mm}$ C18 $\mu\text{Bondapak}$ column was used. The flow rate was 1 ml/min and UV detection at wavelength 190 nm was applied. 0.0025 M sodium phosphate buffer, pH 3.5, containing 0.005 M tetrabutylammonium phosphate and 13% methanol was used as mobile phase. Samples were compared to glutathione (oxidized and reduced) reference standard purchased from Sigma Chemical Co. The results were expressed as $\mu\text{mol/g tissue}$ ^{28, 29}.

2.4.2.5. Determination of tissue MDA (nmol/g tissue) by HPLC:

For determination of MDA levels; the samples were analyzed on an Agilent HP 1200 series HPLC apparatus (USA) as described above. The analytical column was Supelcosil C18 ($5\mu\text{m}$ particle and 80 \AA pore size) ($250 \times 4.6\text{ ID}$). The mobile phase was 82.5:17.5 (v/v) 30 mM monobasic potassium phosphate (pH 3.6)–methanol and the flow rate was 1.2 ml/min , wavelength 250 nm was applied for detection. MDA standard was prepared by dissolving $25\mu\text{l}$ 1,1,3,3 tetraethoxypropane (TEP) in 100 ml of water to give a 1 mM stock solution. Working standard was prepared by hydrolysis of 1 ml TEP stock solution in 50 ml 1% sulfuric acid and incubation for 2 h at room temperature. The resulting MDA standard of 20 nmol/ml was further diluted with 1% sulfuric acid to yield the final concentration of 1.25 nmol/ml to get the standard for the estimation of total MDA ³⁰⁻³².

2.4.2.6. Determination of tissue NO_x ($\mu\text{mol/g tissue}$) by HPLC:

Liver NO_x level was determined using Agilent HP 1200 series HPLC apparatus (USA) as described above. The analytical column was anion exchange PRP-X100 Hamilton, $150 \times 4.1\text{ mm}$, $10\mu\text{m}$. The mobile phase was a mixture of 0.1 M NaCl - methanol, at a volume ratio 45:55. The flow rate of 2 ml/min , wavelength adjusted to 230 nm . The resulting chromatogram identified the concentration from the sample as compared to that of the standard purchased from Sigma Aldrich ³³.

2.4.2.7. Determination of tissue 8-OHDG (pg/g tissue) by HPLC:

The separation of 8-OHDG was performed with an Agilent HP 1200 series HPLC apparatus (USA) as described above. The analytical column was Supelcosil C18 ($5\mu\text{m}$ particle and 80 \AA pore size) ($250 \times 4.6\text{ ID}$). The eluting solution was H₂O/methanol at a ratio (85: 15) with 50 mM KH₂PO₄, pH 5.5 at a flow rate of 0.68 ml/min . the UV detector was set at 245 nm . The resulting chromatogram identified the concentration from the sample as compared to that of the standard purchased from Sigma Aldrich ³⁴.

2.4.2.8. Determination of tissue ATP, ADP and AMP ($\mu\text{g/g tissue}$) by HPLC:

The separation of tissue ATP, ADP and AMP was performed with an Agilent HP 1200 series HPLC apparatus (USA) as described above. The analytical column was Ultrasphere ODS EC $250 \times 4.6\text{ mm}$ column. Mobile phase A consisted of 0.06 mol/l K₂HPO₄ and 0.04 mol/l KH₂PO₄ dissolved in deionized water and adjusted to pH 7.0 with 0.1 mol/l KOH, while mobile phase B consisted of 100 % acetonitrile. Flow rate of the mobile phase was 1.2 ml/min . ATP, ADP and AMP in the samples were identified by comparison with standards purchased from Sigma Aldrich. The report and chromatograms were taken from chemstation program at wave length 254 nm ^{35, 36}.

Total adenylate energy charge (AEC) was calculated according to the equation:

$$\text{AEC} = (\text{ATP} + 0.5\text{ADP}) / (\text{ATP} + \text{ADP} + \text{AMP})^{37}.$$

2.4.2.9. Determination of tissue TNF- α (pg/ g tissue)

The TNF- α , levels were measured using an enzyme-linked immunosorbent assay (ELISA) according to manufacturer's instructions. All of the samples and standards were assayed in duplicate, as suggested by the manufacturer (Rat TNF- α ELISA KIT KOMA BIOTECH INC, Korea)³⁸

2.4.3. Histopathological examination

Liver specimens were taken from all rats subjected to our study, which were sliced and fixed in 10% buffered formalin. Paraffin blocks were prepared from those samples after a serial of dehydration, clearing and embedding. The paraffin-embedded material was prepared in 5- μ m-thick slices, which were stained with hematoxylin and eosin, mounted on microscope slides and examined by optical microscopy to evaluate the morphologic aspects. Furthermore, Section were taken on charged slides to be stained immunohistochemically by Caspase-3 and PCNA antibodies.

Immunohistochemistry for caspase-3 and PCNA.

Immunohistochemistry for caspase-3 and proliferating cell nuclear antigen (PCNA) was performed on formalin-fixed; paraffin-embeded tissue on positively charged slides. Sections mounted on charged slides were de-paraffinized in xylene, hydrated in graded alcohol, and pretreated for antigen retrieval in 10 mmol/l citrate buffer, pH 6.0, in a steamer at 98°C for 45 min. For caspase-3 staining was performed using commercial kit (PharMingen, San Diego, CA, USA). Caspase-3 stained figures were either immuno-positive apoptotic bodies or pre-apoptotic hepatocytes showing cytoplasmic and/or nuclear caspase-staining. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) was performed with a commercial kit (LSAB2 Kit; Dako, Kyoto, Japan). PCNA-positive hepatocytes were compared between the different groups. The use of PCNA protein determinations was used as qualitative measure of hepatic regenerative activity in rats.

Statistical analysis:

Statistical analysis was carried out using one way ANOVA followed by Tukey's multiple comparisons test. $P < 0.05$ was accepted as being significant in all types of statistical tests. Graph prism software (version 6) was used to carry out all statistical tests. Values were expressed as means \pm S.E.

Results

Acute and sub-acute protection against carrageenan-induced inflammation.

Acute effect of combining resveratrol with ibuprofen on carrageenan induced paw edema.

Carrageenan injection resulted in severe paw edema that increased by time. Ibuprofen dose dependently exhibited an anti-inflammatory effect against carrageenan-induced inflammation. Resveratrol on the other hand dose dependently displayed milder anti-inflammatory activity that gradually increased by time. Furthermore; combining resveratrol with ibuprofen resulted in a synergistic anti-inflammatory response that increased by time (Table1).

Table 1. Acute effect of combining resveratrol with ibuprofen on carrageenan induced paw edema.

Time(h) Groups	% Edema			%Inhibition		
	1 st	2 nd	3 rd	1 st	2 nd	3 rd
Carrageenan	83.37 \pm 1.02	86.12 \pm 0.74	89.79 \pm 1.63			
I20	51.17 \pm 1.47*	28.1 \pm 1.04*	18.00 \pm 0.90*	38.62	67.37	79.95
R20	53.13 \pm 1.66*	34.78 \pm 0.54*	26.95 \pm 0.53*	36.27	59.61	69.99
RI20	49.26 \pm 1.10*	27.49 \pm 1.28*	14.48 \pm 0.34*	40.91	68.08	83.87
I40	34.76 \pm 2.57*	24.52 \pm 0.54*	13.19 \pm 1.45*	58.31	71.53	85.31
R40	44.29 \pm 2.40*	30.59 \pm 1.43*	19.95 \pm 0.67*	46.88	64.48	77.78
RI40	27.63 \pm 1.08*	23.40 \pm 0.34*	10.50 \pm 0.40*	66.86	72.83	88.31

*significantly different from acute carrageenan group

Acute and sub-acute effects of combining resveratrol with ibuprofen on serum arachidonic acid and PGE2 levels

Serum samples collected on both day one and day five showed that; carrageenan significantly elevated the levels of both arachidonic acid and prostaglandin E2 as compared to normal control and this effect persisted from day one to day five. Ibuprofen dose dependently exhibited an anti-inflammatory effect against carrageenan-induced inflammation and this effect increased by sub-acute administration for five days. Resveratrol on the other hand dose dependently displayed a mild anti-inflammatory activity that gradually increased by sub-acute administration. Furthermore; combining resveratrol with ibuprofen resulted in a synergistic anti-inflammatory response that increased by sub-acute administration (Table 2).

Table 2. Acute and sub-acute effects of combining resveratrol with ibuprofen on serum arachidonic acid and PGE2 levels

Groups	Arachidonic acid (pg/ml)		PGE2 (pg/ml)	
	Acute	Sub-acute	Acute	Sub-acute
Normal	$66.77 \pm 2.02^{*@}$		$53.65 \pm 0.26^{*@}$	
Carrageenan	$148.90 \pm 2.51^{#@}$	$243.60 \pm 5.35^{*}$	$181.2 \pm 3.12^{#}$	$179.7 \pm 5.38^{#}$
I20	$119.90 \pm 1.29^{**@}$	$109.10 \pm 2.26^{**@}$	$133.4 \pm 2.51^{**@}$	$111.7 \pm 1.60^{**@}$
R20	$132.80 \pm 2.21^{**@}$	$125.20 \pm 2.16^{**@}$	$138.0 \pm 1.83^{**@}$	$128.6 \pm 1.29^{**@}$
RI20	$103.30 \pm 0.67^{**@}$	$77.69 \pm 3.17^{*@}$	$122.3 \pm 1.66^{**@}$	$104.1 \pm 2.86^{**@}$
I40	$113.20 \pm 1.16^{**@}$	$99.39 \pm 1.22^{**@}$	$124.4 \pm 0.25^{**@}$	$101.1 \pm 1.86^{**@}$
R40	$117.00 \pm 1.47^{**@}$	$106.40 \pm 1.38^{**@}$	$127.7 \pm 1.45^{**@}$	$108.7 \pm 1.45^{**@}$
RI40	$80.44 \pm 1.31^{**@}$	$70.34 \pm 1.13^{*@}$	$83.42 \pm 2.55^{**@}$	$72.23 \pm 1.55^{**@}$

significantly different from normal control, *significantly different from acute carrageenan group, @ significantly different from chronic carrageenan group

Sub-acute effect of combining resveratrol with ibuprofen on liver tissue level of TNF- α .

Carrageenan resulted in significant increase in liver tissue TNF- α level as compared to the normal control (654.2 ± 5.62 vs. 389.7 ± 4.71 pg/g tissue). Combining resveratrol with ibuprofen showed augmented anti-inflammatory response by dose dependently significantly reducing liver tissue TNF- α level as compared to carrageenan group (470.7 ± 2.2 and 441.5 ± 5.72 pg/g tissue) respectively (Figure 1).




Figure1. Sub-acute effect of combining resveratrol with ibuprofen on liver tissue level of TNF- α .

significantly different from normal control, @ significantly different from chronic carrageenan group

Acute and sub-acute protection against carrageenan induced liver insult**Acute and sub-acute effects of combining resveratrol with ibuprofen on serum ALT and AST levels.**

Carrageenan resulted in significant elevation in ALT and AST levels that persisted and increased from day one to day five as compared to normal control. Ibuprofen treatment alone was found to be nearly non-protective against carrageenan-induced elevation in liver enzymes and moreover even insulting by itself as the dose and duration of administration increased. On the other hand; resveratrol dose-dependently showed significant protection against the increase in the liver enzymes levels. Finally; combining resveratrol with ibuprofen dose dependently protected against carrageenan- induced elevation in ALT and AST levels as compared to the use of ibuprofen alone. (Table 3).

Table 3. Acute and sub-acute effects of combining resveratrol with ibuprofen on serum ALT and AST levels.

Groups	ALT (u/l)		AST (u/l)	
	Acute	Sub-acute	Acute	Sub-acute
Normal	48.36 ± 0.50 * [@]		90.20 ± 1.97* [@]	
Carrageenan	63.68 ± 1.53 ^{#@}	78.43 ± 1.58 ^{#*}	118.1 ± 1.05 [#]	119.2 ± 0.73 [#]
I20	56.02 ± 0.62 ^{#*[@]}	76.02 ± 2.37 ^{#*}	99.51 ± 2.10 ^{#*[@]}	112.2 ± 0.88 [#]
R20	53.52 ± 0.79 * [@]	68.95 ± 1.09 ^{#[@]}	97.95 ± 2.24 ^{#*[@]}	95.59 ± 1.05 * [@]
RI20	54.31 ± 0.50* [@]	75.45 ± 1.52 ^{#*}	98.92 ± 1.84 ^{#*[@]}	108.9 ± 1.21 ^{#*[@]}
I40	63.94 ± 2.26 ^{#[@]}	83.18 ± 0.71 ^{#*}	105.6 ± 2.05 ^{#*[@]}	118.3 ± 0.707 [#]
R40	52.69 ± 1.29 * [@]	66.03 ± 2.33 ^{#[@]}	92.60 ± 1.28 * [@]	91.46 ± 0.82 * [@]
RI40	62.78 ± 1.50 ^{#[@]}	69.10 ± 2.02 ^{#[@]}	93.22 ± 1.15 * [@]	99.22 ± 1.56 ^{#*[@]}

significantly different from normal control, *significantly different from acute carrageenan group, @ significantly different from chronic carrageenan group.

Sub-acute effect of combining resveratrol with ibuprofen on liver tissue cell energy performance.

Carrageenan resulted in significant disruption in hepatic cells energy represented by increased AMP/ATP ratio as well as significant decrease in adenylate energy charge (AEC) as compared to the normal control. Combining resveratrol with ibuprofen dose dependently reversed that disruption in cell energy; decreasing the AMP/ATP ratio as well as normalizing the AEC (Table 4).

Table 4. Sub-acute effects of combining resveratrol with ibuprofen on liver tissue cell energy performance.

Groups	ATP (ug/g tissue)	ADP (ug/g tissue)	AMP (ug/g tissue)	AMP/ATP	AEC
Normal	28.74 ± 0.18 [@]	15.39 ± 0.18 [@]	9.47 ± 0.25 [@]	0.33 ± 0.01 [@]	0.68 ± 0.003 [@]
Carrageenan	11.05 ± 0.18 [#]	7.57 ± 0.20 [#]	4.69 ± 0.24 [#]	0.43 ± 0.02 [#]	0.64 ± 0.01 [#]
I20	15.62 ± 0.22 ^{#[@]}	9.73 ± 0.37 ^{#[@]}	6.13 ± 0.12 ^{#[@]}	0.39 ± 0.01 [#]	0.65 ± 0.004 [#]
R20	14.99 ± 0.20 ^{#[@]}	9.26 ± 0.23 ^{#[@]}	5.33 ± 0.14 [#]	0.36 ± 0.01 [@]	0.66 ± 0.002 [@]
RI20	19.98 ± 0.26 ^{#[@]}	12.82 ± 0.22 ^{#[@]}	6.92 ± 0.06 ^{#[@]}	0.35 ± 0.004 [@]	0.66 ± 0.002 [@]
I40	16.67 ± 0.46 ^{#[@]}	10.5 ± 0.28 ^{#[@]}	6.05 ± 0.20 ^{#[@]}	0.36 ± 0.01 [@]	0.65 ± 0.01 [#]
R40	17.85 ± 0.27 ^{#[@]}	11.18 ± 0.24 ^{#[@]}	6.18 ± 0.21 ^{#[@]}	0.33 ± 0.01 [@]	0.67 ± 0.01 [@]
RI40	24.08 ± 0.45 ^{#[@]}	13.7 ± 0.25 ^{#[@]}	8.27 ± 0.22 ^{#[@]}	0.34 ± 0.01 [@]	0.68 ± 0.01 [@]

significantly different from normal control, @ significantly different from carrageenan control.

Sub-acute effect of combining resveratrol with ibuprofen on liver tissue 8-OHdG level.

Carrageenan resulted in significant increase in the 8-OHdG level indicating the incidence of hepatic tissue DNA fragmentation (526.4 ± 5.95 vs. 220.1 ± 6.15 pg/g tissue) as compared to the normal control. Ibuprofen alone at the lower dose showed pronounced protection against hepatic tissue increase in the 8-OHdG level. This protection decreased as the dose increased indicating that sub-

acute administration of ibuprofen could itself be insulting to the liver tissue. On the other hand resveratrol combination with ibuprofen resulted in augmented hepatoprotective effect (Figure 2).




Figure 2. Sub-acute effects of combining resveratrol with ibuprofen on liver tissue 8-OHdG level.

significantly different from normal control, @ significantly different from carrageenan control.

Sub-acute effects of combining resveratrol with ibuprofen on liver tissue oxidative and nitrosative stresses parameters.

Sub-acute effect of combining resveratrol with ibuprofen on liver tissue GSH, GSSG, MDA and NOx levels

Carrageenan resulted in significant increase in the level of the oxidized form of glutathione (GSSG) (0.69 ± 0.02 vs. 1.83 ± 0.05 $\mu\text{mol/g}$ tissue) and decrease in the level of the reduced form of glutathione (GSH) (15.83 ± 0.38 vs. 35.19 ± 0.85 $\mu\text{mol/g}$ tissue) and consequently increasing the GSSG/GSH ratio and furthermore; elevated MDA and NOx levels (41.76 ± 1.67 vs. 13.35 ± 0.29 nmol/g tissue) and (1.78 ± 0.06 vs. 0.52 ± 0.03 $\mu\text{mol/g}$ tissue) respectively as compared to normal control, indicating pronounced oxidative stress and nitrosative stress. Combining resveratrol with ibuprofen dose dependently significantly decreased GSSG/GSH ratio, MDA and NOx levels as compared to carrageenan control indicating augmented protection against oxidative and nitrosative stresses (Figures 3, 4, 5).




Figure 3. Sub-acute effect of combining resveratrol with ibuprofen on liver tissue GSSG/ GSH ratio.

significantly different from normal control, @ significantly different from carrageenan control.




Figure 4. Sub-acute effect of combining resveratrol with ibuprofen on liver tissue MDA level.

significantly different from normal control, @ significantly different from carrageenan control.




Figure 5. Sub-acute effect of combining resveratrol with ibuprofen on liver tissue NOx level.

significantly different from normal control, @ significantly different from carrageenan control.

Histochemical and immunohistochemical studies

Carrageenan sub-planter injection resulted in serious hepatic tissue insult represented by clearly seen vacuolar cytoplasmic degeneration along the three hepatic zones, large bi-nucleated acidophilic cell, areas of necrosis and nuclear DNA fragmentation as seen on H&E stain. Furthermore; immunohistochemical evaluation of Caspase-3 demonstrated positively stained hepatocytes along the three hepatic zones with the nuclei showing chromatin condensation in some of them. Moreover; assessment of PCNA showed scattered faintly positive nuclei along the hepatic lobule.

Ibuprofen at the lower dose (20 mg/kg p.o) showed areas of necrosis in the hepatic tissue along with congestion in central vein and more vacuolar degeneration in zone 2 than zone 3 in H &E stained sections. As for the immunohistochemical evaluations; minimal stained nuclei were seen with caspase-3 as well as PCNA negative stain in the group ingesting the low dose of ibuprofen as no regeneration took place without a hepatoprotective drug administration. As for the group ingesting resveratrol at the low dose level alone; thickening of central vein wall without congestion and less areas of necrosis than the group ingesting ibuprofen (20 mg/kg) were revealed in H &E stain. Caspase-3 stain showed mixed pattern of staining with positive and negative stained nuclei. Moreover; PCNA stain showed few positive stained cells with granular nuclei. So we can say that the cells are affected but not fully saved by the low dose of resveratrol. Combination of ibuprofen with resveratrol at the low dose levels in H &E stain showed areas of necrosis and vacuolar degeneration and the results were better than the group ingesting the lower dose of ibuprofen alone and close to that ingesting resveratrol at the low dose level alone. The results were confirmed at the level of Caspase-3 where; minimal scattered faintly stained cells less than 1-2 per high power field were observed. PCNA stain revealed faint positively stained nuclei indicating active cellular division and DNA repair. So the combination group in low dose has a favorable picture than low dose ibuprofen and we can say that its morphology lies in between the low dose of ibuprofen and the low dose resveratrol.

On the other side ibuprofen at the high dose (40 mg/kg) showed vesicular nuclei alongside with cytoplasmic vacuolar degeneration and extensive areas of necrosis in H &E stain. The overall picture was near to carrageenan control where the hepatocytes were much affected by the toxic effects of carrageenan as well as the effect of added ibuprofen. The picture was additionally proved on immunohistochemistry level where; caspase-3 stain showed many positive cells with fragmented chromatin and moreover; PCNA showed few stained cells with mild faint homogenous stain with minimal granular distribution.

The group ingesting resveratrol at the higher dose (40 mg/kg) showed vacuolar degeneration of cytoplasm and fragmented nuclei but no areas of necrosis. Results of this group is better than ibuprofen at the low and high dose as well as resveratrol at the low dose level and the RI20 combination. On immunohistochemistry level; caspase-3 stain revealed relatively strongly stained cells expressing spontaneous apoptosis as a protective physiological process. PCNA stain showed moderate positivity with weak intensity revealing cellular regeneration in a higher rate than in case of ingesting resveratrol at the lower dose.

The group ingesting ibuprofen in combination with resveratrol in the high dose showed overcrowded cells as well as minimal areas of necrosis, results were better than using either treatments alone at the high dose level. On immunohistochemical analysis levels; minimal scattered faintly stained cells less than 1-2 per five high power fields in case of caspase-3 stain were observed. PCNA stain revealed high positivity indicating active cellular division and DNA repair. Finally combinations of resveratrol and ibuprofen at the high dose levels revealed much better results than all groups (Figures 6, 7, 8).

Figures pathology

Figure 6 (a). Normal hepatic tissue X100:




Figure 6. (a): Normal hepatic tissue showing normal hepatic architecture

Figure 6 (b). Carrageenan control X100:




Figure 6 (c). Carrageenan control X400:




Figure 6. (b, c): Carrageenan control showing vacuolar cytoplasmic degeneration along the three hepatic zones, large bi-nucleated acidophilic cell, areas of necrosis and nuclear DNA fragmentation.

Figure 6. (d). Ibuprofen (20 mg/kg) X100:




Figure 6. (d): Ibuprofen (20 mg/kg) group showing congested central vein, vacuolar degeneration more in zone two than zone three and areas of necrosis.

Figure 6. (e). Resveratrol (20 mg/kg)X100: Figure 6.(f).Resveratrol (20 mg/kg)X400:





Figure 6. (e, f): Resveratrol (20 mg/kg) group showed thickening of central vein wall without congestion. At higher power examination revealed areas of necrosis less than carrageenan and I20 groups but more than RI20 group.

Figure 6. (g). RI (20 mg/kg) X100:




Figure 6. (h). RI (20 mg/kg) X400:




Figure 6. (g, h): RI (20 mg/kg) showing mild necrosis and vacuolar degeneration.

Figure 6. (i). Ibuprofen (40 mg/kg) X100: Figure 6. (j). Ibuprofen (40 mg/kg) X400:





Figure 6. (i, j): Ibuprofen (40 mg/kg) group showing vesicular nuclei, cytoplasmic vacuolar degeneration and extensive areas of necrosis.



Figure 6.(k).Resveratrol (40 mg/kg)X100:**Figure 6. (l). Resveratrol (40 mg/kg)X400:**

Figure 6. (k, l): Resveratrol (40 mg/kg) group showing vacuolar degeneration of cytoplasm and fragmented nuclei but no areas of necrosis.



Figure 6. (m). RI (40 mg/kg) X100:**Figure 6. (n). RI (40 mg/kg) X400:**

Figure 6. (m, n): RI (40 mg/kg) group at lower power, photomicrography revealed non congested central vein, overcrowded cells as well as minimal areas of necrosis. At higher power, cytoplasm is preserved in most of cells, nuclei are vesicular and active.

Immunohistochemical figures

Casepase-3 stain


Figure 7. (a). Normal hepatic tissue

Figure 7. (a): Normal hepatic tissue photomicrography showing negative staining for caspase-3



Figure 7. (b). Carrageenan control X100:

Figure 7. (b). Carrageenan control group showed positively stained hepatocytes along the three hepatic zones where the nuclei showing chromatin condensation in some of them.




Figure 7. (c). Ibuprofen (20 mg/kg) X100:	Figure 7. (d). Ibuprofen (20 mg/kg) X 400:	Figure 7. (e). Resveratrol (20 mg/kg) X100:
		
Figure 7. (c, d). Ibuprofen (20 mg/kg) group showed minimal stained nuclei with caspase-3 indicating that low dose of ibuprofen could be tolerated by liver cells.	Figure 7. (e). Resveratrol (20 mg/kg) group showed mixed pattern of staining with positive and negative stained nuclei indicating that the cells are affected but not fully saved by the low dose of resveratrol.	



Figure 7. (f). RI (20 mg/kg) X100**Figure 7. (g). RI (20 mg/kg) X400**

Figure 7. (f, g). RI (20 mg/kg) group showed minimal scattered faintly stained cells less than 1-2 per high power field.



Figure 7. (h). Ibuprofen (40 mg/kg) X100: Figure 7.(i). Resveratrol (40 mg/kg) X100:

Figure 7. (h). Ibuprofen (40 mg/kg) group showed many positive cells with fragmented chromatin.

Figure 7. (i). Resveratrol (40 mg/kg) group showed relatively strongly expressed caspase-3 stain; as part of the cells underwent spontaneous apoptosis as a protective physiological process

Figure 7. (j). RI (40 mg/kg) X100:




Figure 7. (k). RI (40 mg/kg) X400:




Figure 7. (j, k). RI (40 mg/kg) group showed minimal scattered faintly stained cells less than 1-2 per five high power fields.

PCNA

Figure 8 (a). Normal hepatic tissue X100:




Figure 8 (a). Normal hepatic tissue showing scattered positive cells indicating active regeneration of liver cells.

Figure 8 (b). Carrageenan control X100:




Figure 8 (b). Carrageenan control showed scattered faintly positive nuclei along the hepatic lobule.







Figure 8 (c). Ibuprofen (20 mg/kg) X100: Figure 8 (d). Resveratrol (20 mg/kg) X100:**Figure 8 (c).** Ibuprofen (20 mg/kg) group showed negative stain as no regeneration took place without a hepatoprotective drug administration.**Figure 8 (d).** Resveratrol (20 mg/kg) group showed few positive stained cells with granular nuclei.**Figure 8 (e). RI (20 mg/kg) X100:****Figure 8 (e).** RI (20 mg/kg) group showed faint positivity stained nuclei indicating active cellular division and DNA repair.**Figure 8 (f). Ibuprofen (40 mg/kg) X100: Figure 8 (g). Resveratrol (40 mg/kg) X100:****Figure 8 (f).** Ibuprofen (40 mg/kg) group showed PCNA few stained cells with mild faint homogenous stain with minimal granular distribution.**Figure 8 (g).** Resveratrol (40 mg/kg) group showed PCNA moderate positivity with weak intensity revealing cellular regeneration in a higher rate than R20.

Figure 8 (h). RI (40 mg/kg) X100:**Figure 8 (h).** RI (40 mg/kg) group showed PCNA high positivity indicating highly active cellular division and DNA repair.

Discussion

Inflammation is an important sign of many pathological diseases including rheumatoid arthritis, periodontitis and cancer. It progresses through the prostaglandin (PG) and leukotriene (LT) pathways starting with the release of arachidonic acid (AA) from the membrane lipid bilayer³⁹. Arachidonic acid (AA) pathway leads to the generation of the proinflammatory biochemical mediators and is a critical component of inflammation. The first and key step in the activation of this pathway is the generation of a large pool of AA from membrane phospholipids by the action of phospholipase A2 (PLA2). Subsequently, AA is metabolized by lipoxygenase (LOX), cyclooxygenase (COX) and their respective downstream enzymes resulting in the production of eicosanoids such as leukotrienes (LTs), prostaglandins (PGs) and thromboxanes (TXs)⁴⁰. Furthermore; tumor necrosis factor- α (TNF- α) is a cell signaling protein (cytokine) possessing a major role in systemic inflammation and is responsible for the acute phase reaction⁴¹. Biochemical energy is the fundamental element to maintain the turnover of the bio-molecular structures and the functional metabolic viability of all unicellular organisms. The concentration levels of ATP, ADP and AMP reflect roughly the energetic status of cells, and a determined ratio between them was proposed by Atkinson as the adenylate energy charge (AEC).⁴² Attenuation of energy deficits indicated by increased ATP and adenylate energy charge levels, and decreased AMP/ATP ratio could be used as reliable markers indicating protection against tissue injury⁴³. Moreover; oxidative and nitrosative stresses represent well-established and reliable indicators of existence of tissue insult^{1, 44}. Another parameter that assess the occurrence of tissue insult is the percent of tissue DNA damage. An important cause of DNA damage concerns the attack by reactive oxygen species, leading to DNA hydroxylation. Oxidizing DNA to form 8-hydroxy-2-deoxyguanosine (8-OHDG) adducts; a major species of oxidative DNA damage⁴⁵. 8-OHDG content is considered a sensitive biomarker of the oxidative DNA damage and repair⁴⁶. Proliferating cell nuclear antigen (PCNA) is a cell cycle marker protein that functions as sliding clamp during DNA replication⁴⁷. PCNA is involved in the DNA damage tolerance pathway known as post-replication repair.⁴⁸ PCNA is used in the study of the dynamics of replication and repair in living cells by detecting its introducing translational fusions. This is done by examining cells undergoing repair and showing PCNA positive stain⁴⁹ Caspase-3 has long been recognized as a key protease mediating cell demolition during apoptotic cell death. Numerous nuclear substrates for caspase-3 have been recognized although procaspase-3 is mainly localized in the cytoplasm. Recent studies revealed that caspase-3 could to an extent increase the production of PGE2 via a caspase-3-activated signaling pathway involving cytosolic calcium-independent phospholipase A2 and arachidonic acid⁵⁰⁻⁵²

Carrageenans are classically used as agents for the induction of experimental inflammation and inflammatory pain. Studies in mammals have demonstrated that carrageenan exposure predictably causes inflammation, including development of ulcerations, polyps, colitis, and colorectal tumors, and since then; carrageenan has been used in thousands of cell-based and animal experiments to cause inflammation, primarily to study mediators of inflammation and anti-inflammatory therapeutics.

Moreover; carrageenan was found to induce acute and chronic hepatic injury in many animal models. The mechanism underlying carrageenan-induced hepatic injury could be explained by the fact that carrageenan could be detected within Kupffer cells, where it persists for several months; leading to the impairment of Kupffer cells' activity. It is possible that damage to hepatic parenchymal cells is caused by proteolytic enzymes released from carrageenan-damaged Kupffer cells. Furthermore; it was demonstrated that single intraperitoneal carrageenan injection into mice (1 mg/0.2 ml/mouse) resulted in prominent activation of natural killer (NK) cells in the liver, lungs, and spleen. A time-kinetic study showed sequential activation of NK and natural killer T (NKT) cells in the liver on days 3–7 after the injection. In parallel with the activation of NK and NKT cells in number, NK and NKT cytotoxicities were augmented. At this time, liver injury was induced, accompanied by massive hepatic necrosis and the elevation of transaminases. The In-vivo elimination of NK cells reduced the liver injury induced by carrageenan. These findings suggest that not only phagocytic cells but also primitive lymphocyte (mainly NK cells) subsets might be important targets for the acute toxicity of carrageenan^{2, 7, 53, 54}.

In the present study single sub-planter injection of carrageenan resulted in severe paw edema, accompanied with a major increase in serum and liver inflammatory biomarkers namely; AA, PGE2 and TNF- α that lasted for several days after carrageenan injection. Additionally; carrageenan injection resulted in pronounced oxidative and nitrosative stress, noticeable decrease in adenylate energy charge (AEC) and marked increase in 8-OHDG level. Besides; histopathological and immunohistochemical examination revealed definite hepatic tissue injury.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are notably used worldwide for the treatment of inflammatory diseases⁵⁵. They exert their efficacy through inhibition of cyclooxygenase (COX), a key enzyme for the biosynthesis of proinflammatory molecules, such as PGE2, prostaglandin I2, and thromboxane⁵⁶. Unfortunately NSAIDs share a common spectrum of clinical toxicities; of the most hazardous and particularly important in patients are the renal, hepatic, and cardio-vascular toxicities. Small elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (approximately ≥ 3 times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials of NSAIDs⁵⁷. Ibuprofen, as an example of NSAID showed moderate hepatotoxicity in rats⁵⁸. It is one of the NSAIDs that are commonly known to produce hepatotoxicity through inducing cholestatic hepatitis⁵⁹. Four weeks chronic treatment with ibuprofen (0.4 g/kg/day i.p) demonstrated a sequence of pathologies, not formerly stated in ibuprofen-treated rats, mainly; hepatic encephalopathy, hepatomegaly, increased AST and ALT serum values⁶⁰. Resveratrol has long been acknowledged to possess anti-oxidative, anti-inflammatory and hepatoprotective properties^{17, 61}. Several studies highlighted the beneficial outcomes from using resveratrol in the protection against and treatment of liver injury either alone or in combination with other medications or nutraceuticals. It was demonstrated that; resveratrol pretreatment protected against [D-galactosamine (800 mg/kg) + lipopolysaccharide (LPS; 0.5 ug/kg)] induced liver failure in rats. Among the mechanisms responsible for the hepatoprotective effect of resveratrol in this model were the reduction in nitrosative stress and modification of oxidative stress parameters which led to overall improvement in hepatotoxic markers and morphology after the hepatic insult⁶². Previous researchers stated that resveratrol was able to reduce inflammation via inhibition of prostaglandin production, cyclooxygenase-2 activity, and nuclear factor- κ B (NF- κ B) activity and due to the probability that inflammatory mediators may stimulate hepatic stellate cell (HSC) activation, it is possible that the anti-inflammatory effect of resveratrol may contribute to its anti-fibrotic activity in the injured liver via inhibition of HSC activation^{63, 64}. Several in vitro studies have documented the inhibition of stellate cell activation by resveratrol using rat HSCs and cultured human liver myofibroblasts^{65, 66}. The hepatoprotective and anti-fibrogenic effects of resveratrol have been reported recently in several models of rat liver injuries^{67, 68}.

In the present study; ibuprofen ingestion resulted in reversal of carrageenan induced inflammatory signs but failed to show discernible protection against the carrageenan-induced liver insult especially as the ingested dose increased. On the other hand combining resveratrol with ibuprofen resulted in augmented anti-inflammatory and hepato-protective effects represented by acute protection against carrageenan induced paw edema, pronounced decline in serum arachidonic acid, PGE2, ALT and AST

levels after both single and repeated administration, reduction in hepatic TNF- α level and 8-OHdG content, improvement in hepatic tissue cell energy performance, amelioration of oxidative and nitrosative stresses. Finally both histochemical and immunohistochemical evaluations showed the beneficial outcomes from combining both treatments.

Conclusion

The present study revealed that combining resveratrol with ibuprofen to combat inflammation could be beneficial by augmenting the anti-inflammatory effect as well as protection against the hepatic insult that could occur when using ibuprofen alone.

References

1. Middha S.K., Goyal A.K., Lokesh P., Yardi V., Mojamdar L., Keni D.S., Babu D. and Usha T. Toxicological Evaluation of Emblica officinalis Fruit Extract and its Anti-inflammatory and Free Radical Scavenging Properties. *Pharmacogn Mag.* 2015; 11: S427-33.
2. Di Rosa M. Biological properties of carrageenan. *J Pharm Pharmacol.* 1972; 24: 89-102.
3. Bhattacharyya S., Dudeja P.K. and Tobacman J.K. Carrageenan-induced NF κ B activation depends on distinct pathways mediated by reactive oxygen species and Hsp27 or by Bcl10. *Biochim Biophys Acta.* 2008; 1780: 973-82.
4. Fecho K., Manning E.L., Maixner W. and Schmitt C.P. Effects of carrageenan and morphine on acute inflammation and pain in Lewis and Fischer rats. *Brain Behav Immun.* 2007; 21: 68-78.
5. Li M., Lu C., Zhang L., Zhang J., Du Y., Duan S., Wang T. and Fu F. Oral Administration of Escin Inhibits Acute Inflammation and Reduces Intestinal Mucosal Injury in Animal Models. *Evid Based Complement Alternat Med.* 2015; 2015: 503617.
6. Kandimalla R., Dash S., Kalita S., Choudhury B., Malampati S., Kalita K., Kalita B., Devi R. and Kotoky J. Protective Effect of Bioactivity Guided Fractions of Ziziphus jujuba Mill. Root Bark against Hepatic Injury and Chronic Inflammation via Inhibiting Inflammatory Markers and Oxidative Stress. *Front Pharmacol.* 2016; 7: 298.
7. Abe T., Kawamura H., Kawabe S., Watanabe H., Gejyo F. and Abo T. Liver injury due to sequential activation of natural killer cells and natural killer T cells by carrageenan. *J Hepatol.* 2002; 36: 614-23.
8. Costa B., Conti S., Giagnoni G. and Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclooxygenase systems. *Br J Pharmacol.* 2002; 137: 413-20.
9. Curiel R.V. and Katz J.D. Mitigating the cardiovascular and renal effects of NSAIDs. *Pain Med.* 2013; 14 Suppl 1: S23-8.
10. Wood D.M., Monaghan J., Streete P., Jones A.L. and Dargan P.I. Fatality after deliberate ingestion of sustained-release ibuprofen: a case report. *Crit Care.* 2006; 10: R44.
11. Lodise M., De-Giorgio F., Rossi R., d'Aloja E. and Fucci N. Acute Ibuprofen intoxication: report on a case and review of the literature. *Am J Forensic Med Pathol.* 2012; 33: 242-6.
12. Angadi S.S. and Karn A. Ibuprofen induced Stevens-Johnson syndrome - toxic epidermal necrolysis in Nepal. *Asia Pac Allergy.* 2016; 6: 70-3.
13. Donati M., Conforti A., Lenti M.C., Capuano A., Bortolami O., Motola D., Moretti U., Vannacci A., Rafaniello C., Vaccheri A., Arzenton E., Bonaiuti R., Sportiello L., Leone R. and Group D.-I.S. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. *Br J Clin Pharmacol.* 2016; 82: 238-48.
14. Mengual-Moreno E., Lizarabal-Garcia M., Ruiz-Soler M., Silva-Suarez N., Andrade-Bellido R., Lucena-Gonzalez M., Bessone F., Hernandez N., Sanchez A. and Medina-Caliz I. [Case reports of drug-induced liver injury in a reference hospital of Zulia state, Venezuela]. *Invest Clin.* 2015; 56: 3-12.
15. Nayudu S.K., Kavuturu S., Niazi M., Daniel M., Dev A. and Kumbum K. A rare coexistence: drug induced hepatitis and meningitis in association with Ibuprofen. *J Clin Med Res.* 2013; 5: 243-6.
16. Seif El-Din S.H., El-Lakkany N.M., Salem M.B., Hammam O.A., Saleh S. and Botros S.S. Resveratrol mitigates hepatic injury in rats by regulating oxidative stress, nuclear factor-kappa B, and apoptosis. *J Adv Pharm Technol Res.* 2016; 7: 99-104.

17. Pektas M.B., Sadi G., Koca H.B., Yuksel Y., Vurmaz A., Koca T. and Tosun M. Resveratrol Ameliorates the Components of Hepatic Inflammation and Apoptosis in a Rat Model of Streptozotocin-Induced Diabetes. *Drug Dev Res.* 2016; 77: 12-9.
18. Bishayee A., Darvesh A.S., Politis T. and McGory R. Resveratrol and liver disease: from bench to bedside and community. *Liver Int.* 2010; 30: 1103-14.
19. Mennecozzi M., Landesmann B., Palosaari T., Harris G. and Whelan M. Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro? *PLoS One.* 2015; 10: e0122786.
20. Lacroix I., Lapeyre-Mestre M., Bagheri H., Pathak A., Montastruc J.L., Club de Reflexion des cabinets de Groupe de G.-E. and General Practitioner N. Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. *Fundam Clin Pharmacol.* 2004; 18: 201-6.
21. Gochfeld M. Framework for gender differences in human and animal toxicology. *Environ Res.* 2007; 104: 4-21.
22. Zucker I. and Beery A.K. Males still dominate animal studies. *Nature.* 2010; 465: 690.
23. Straub R.H. The complex role of estrogens in inflammation. *Endocr Rev.* 2007; 28: 521-74.
24. Winter C.A., Risley E.A. and Nuss G.W. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. *Proc Soc Exp Biol Med.* 1962; 111: 544-7.
25. Reitman S. and Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol.* 1957; 28: 56-63.
26. Granstrom E., Hamberg M., Hansson G. and Kindahl H. Chemical instability of 15-keto-13,14-dihydro-PGE₂: the reason for low assay reliability. *Prostaglandins.* 1980; 19: 933-57.
27. Ren J., Mozurkewich E.L., Sen A., Vahratian A.M., Ferreri T.G., Morse A.N. and Djuric Z. Total Serum Fatty Acid Analysis by GC-MS: Assay Validation and Serum Sample Stability. *Curr Pharm Anal.* 2013; 9: 331-9.
28. Yoshida T. Determination of reduced and oxidized glutathione in erythrocytes by high-performance liquid chromatography with ultraviolet absorbance detection. *J Chromatogr B Biomed Appl.* 1996; 678: 157-64.
29. Jayatilleke E. and Shaw S. A high-performance liquid chromatographic assay for reduced and oxidized glutathione in biological samples. *Anal Biochem.* 1993; 214: 452-7.
30. Karatas F., Karatepe M. and Baysar A. Determination of free malondialdehyde in human serum by high-performance liquid chromatography. *Anal Biochem.* 2002; 311: 76-9.
31. Lazzarino G., Di Pierro D., Tavazzi B., Cerroni L. and Giardina B. Simultaneous separation of malondialdehyde, ascorbic acid, and adenine nucleotide derivatives from biological samples by ion-pairing high-performance liquid chromatography. *Anal Biochem.* 1991; 197: 191-6.
32. Karatepe M. Simultaneous Determination of Ascorbic Acid and Free Malondialdehyde in Human Serum by HPLC-UV. *LCGC ASIA PACIFIC.* 2004; 7: 36-8.
33. Papadoyannis I.N., Samanidou V.F. and Nitsos C.C. SIMULTANEOUS DETERMINATION OF NITRITE AND NITRATE IN DRINKING WATER AND HUMAN SERUM BY HIGH PERFORMANCE ANION-EXCHANGE CHROMATOGRAPHY AND UV DETECTION. *Journal of Liquid Chromatography & Related Technologies.* 1999; 22: 2023-41.
34. Lodovici M., Casalini C., Briani C. and Dolara P. Oxidative liver DNA damage in rats treated with pesticide mixtures. *Toxicology.* 1997; 117: 55-60.
35. Teerlink T., Hennekes M., Bussemaker J. and Groeneveld J. Simultaneous determination of creatine compounds and adenine nucleotides in myocardial tissue by high-performance liquid chromatography. *Anal Biochem.* 1993; 214: 278-83.
36. Liu H., Jiang Y., Luo Y. and Jiang W. A Simple and Rapid Determination of ATP, ADP and AMP Concentrations in Pericarp Tissue of Litchi Fruit by High Performance Liquid Chromatography. *Food Technology and Biotechnology.* 2006; 44: 531-4.
37. Atkinson D.E. and Walton G.M. Adenosine triphosphate conservation in metabolic regulation. Rat liver citrate cleavage enzyme. *J Biol Chem.* 1967; 242: 3239-41.

38. Sakamoto K., Arakawa H., Mita S., Ishiko T., Ikei S., Egami H., Hisano S. and Ogawa M. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. *Cytokine*. 1994; 6: 181-6.
39. Ramanan M., Sinha S., Sudarshan K., Aidhen I.S. and Doble M. Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins. *Eur J Med Chem*. 2016; 124: 428-34.
40. Joshi V., Venkatesha S.H., Ramakrishnan C., Nanjaraj Urs A.N., Hiremath V., Moudgil K.D., Velmurugan D. and Vishwanath B.S. Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A2 group IIA, 5-lipoxygenase and cyclooxygenase-2. *Pharmacol Res*. 2016; 113: 265-75.
41. Mu Z.P., Wang Y.G., Li C.Q., Lv W.S., Wang B., Jing Z.H., Song X.J., Lun Y., Qiu M.Y. and Ma X.L. Association Between Tumor Necrosis Factor-alpha and Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes: a Meta-Analysis. *Mol Neurobiol*. 2016.
42. De la Fuente I.M., Cortes J.M., Valero E., Desroches M., Rodrigues S., Malaina I. and Martinez L. On the dynamics of the adenylate energy system: homeorhesis vs homeostasis. *PLoS One*. 2014; 9: e108676.
43. Wang X., Liu Y., Li S., Pi D., Zhu H., Hou Y., Shi H. and Leng W. Asparagine attenuates intestinal injury, improves energy status and inhibits AMP-activated protein kinase signalling pathways in weaned piglets challenged with Escherichia coli lipopolysaccharide. *Br J Nutr*. 2015; 114: 553-65.
44. Meng J., Yu P., Jiang H., Yuan T., Liu N., Tong J., Chen H., Bao N. and Zhao J. Molecular hydrogen decelerates rheumatoid arthritis progression through inhibition of oxidative stress. *Am J Transl Res*. 2016; 8: 4472-7.
45. Aksit H. and Bildik A. Determination of DNA damage in experimental liver intoxication and role of N-acetyl cysteine. *Cell Biochem Biophys*. 2014; 70: 1119-25.
46. Ahmed-Farid O., Ahmed R. and Saleh D. Combination of resveratrol and fluoxetine in an acute model of depression in mice: Prevention of oxidative DNA fragmentation and monoamines degradation. *Journal of Applied Pharmaceutical Science*. 2016: 001-7.
47. Naryzhny S.N. Proliferating cell nuclear antigen: a proteomics view. *Cell Mol Life Sci*. 2008; 65: 3789-808.
48. Tazuke Y., Maeda K., Wasa M., Satoko N. and Fukuzawa M. Protective mechanism of glutamine on the expression of proliferating cell nuclear antigen after cisplatin-induced intestinal mucosal injury. *Pediatr Surg Int*. 2011; 27: 151-8.
49. Essers J., Theil A.F., Baldeyron C., van Cappellen W.A., Houtsmuller A.B., Kanaar R. and Vermeulen W. Nuclear dynamics of PCNA in DNA replication and repair. *Mol Cell Biol*. 2005; 25: 9350-9.
50. Mirzayans R., Andrais B., Kumar P. and Murray D. The Growing Complexity of Cancer Cell Response to DNA-Damaging Agents: Caspase 3 Mediates Cell Death or Survival? *Int J Mol Sci*. 2016; 17.
51. Huang Q., Li F., Liu X., Li W., Shi W., Liu F.F., O'Sullivan B., He Z., Peng Y., Tan A.C., Zhou L., Shen J., Han G., Wang X.J., Thorburn J., Thorburn A., Jimeno A., Raben D., Bedford J.S. and Li C.Y. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. *Nat Med*. 2011; 17: 860-6.
52. Kamada S., Kikkawa U., Tsujimoto Y. and Hunter T. Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s). *J Biol Chem*. 2005; 280: 857-60.
53. Thomson A.W., Fowler E.F., Sljivic V.S. and Brent L. Carrageenan toxicity. *Lancet*. 1980; 1: 1034.
54. Borthakur A., Bhattacharyya S., Anbazhagan A.N., Kumar A., Dudeja P.K. and Tobacman J.K. Prolongation of carrageenan-induced inflammation in human colonic epithelial cells by activation of an NFkappaB-BCL10 loop. *Biochim Biophys Acta*. 2012; 1822: 1300-7.

55. Blanca-Lopez N., Cornejo-Garcia J.A., Perez-Alzate D., Perez-Sanchez N., Plaza-Seron M.C., Dona I., Torres M.J., Canto G., Kidon M., Perkins J.R. and Blanca M. Hypersensitivity Reactions to Nonsteroidal Anti-inflammatory Drugs in Children and Adolescents: Selective Reactions. *J Investig Allergol Clin Immunol*. 2015; 25: 385-95.
56. Nitta M., Kishimoto T., Muller N., Weiser M., Davidson M., Kane J.M. and Correll C.U. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. *Schizophr Bull*. 2013; 39: 1230-41.
57. Crofford L.J. Use of NSAIDs in treating patients with arthritis. *Arthritis Res Ther*. 2013; 15 Suppl 3: S2.
58. Schoonen W.G., Kloks C.P., Ploemen J.P., Smit M.J., Zandberg P., Horbach G.J., Mellema J.R., Thijssen-Vanzuylen C., Tas A.C., van Nesselrooij J.H. and Vogels J.T. Uniform procedure of (1)H NMR analysis of rat urine and toxicometabonomics Part II: comparison of NMR profiles for classification of hepatotoxicity. *Toxicol Sci*. 2007; 98: 286-97.
59. Manov I., Motanis H., Frumin I. and Iancu T.C. Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects. *Acta Pharmacol Sin*. 2006; 27: 259-72.
60. Ilic S., Drmic D., Zarkovic K., Kolenc D., Breic L., Radic B., Djuzel V., Blagaic A.B., Romic Z., Dzidic S., Kalogjera L., Seiwerth S. and Sikiric P. Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. *Eur J Pharmacol*. 2011; 667: 322-9.
61. Chen W.M., Shaw L.H., Chang P.J., Tung S.Y., Chang T.S., Shen C.H., Hsieh Y.Y. and Wei K.L. Hepatoprotective effect of resveratrol against ethanol-induced oxidative stress through induction of superoxide dismutase in vivo and in vitro. *Exp Ther Med*. 2016; 11: 1231-8.
62. Farghali H., Cerny D., Kamenikova L., Martinek J., Horinek A., Kmonickova E. and Zidek Z. Resveratrol attenuates lipopolysaccharide-induced hepatitis in D-galactosamine sensitized rats: role of nitric oxide synthase 2 and heme oxygenase-1. *Nitric Oxide*. 2009; 21: 216-25.
63. Shankar S., Singh G. and Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. *Front Biosci*. 2007; 12: 4839-54.
64. Wallace K., Burt A.D. and Wright M.C. Liver fibrosis. *Biochem J*. 2008; 411: 1-18.
65. Godichaud S., Krisa S., Couronne B., Dubuisson L., Merillon J.M., Desmouliere A. and Rosenbaum J. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. *Hepatology*. 2000; 31: 922-31.
66. Godichaud S., Si-Tayeb K., Auge N., Desmouliere A., Balabaud C., Payrastre B., Negre-Salvayre A. and Rosenbaum J. The grape-derived polyphenol resveratrol differentially affects epidermal and platelet-derived growth factor signaling in human liver myofibroblasts. *Int J Biochem Cell Biol*. 2006; 38: 629-37.
67. Lee E.S., Shin M.O., Yoon S. and Moon J.O. Resveratrol inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. *Arch Pharm Res*. 2010; 33: 925-32.
68. Chavez E., Reyes-Gordillo K., Segovia J., Shibayama M., Tsutsumi V., Vergara P., Moreno M.G. and Muriel P. Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. *J Appl Toxicol*. 2008; 28: 35-43.
